Skip to main content
Clinical Trials/NCT04361760
NCT04361760CompletedNot Applicable

Better to Focus or to Spread? Signal Propagation and Its Relationship to Cognitive Performance in the Aging Human Brain

Insel Gruppe AG, University Hospital Bern2 sites in 1 country40 target enrollmentStarted: June 25, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
40
Locations
2
Primary Endpoint
Age-related differences in the spatio-temporal patterns of signal propagation

Study Overview

Brief Summary

In the next three decades, the world's population over 60 years old is expected to more than double its size. Even in the absence of an obvious pathology (i.e., healthy aging), advancing age is typically associated with a progressive decline in cognitive performance. Although pathophysiological changes in age-related neurodegenerative disorders have received much attention over the past years, far less is known about the neural processes affecting cognition in healthy ageing. One of these postulated processes is neural dedifferentiation (i.e., a decrease in neural selectivity, by which neural representations of processed information become less univocally distinguishable), possibly accompanied by the recruitment of additional cortical areas in the healthy aging brain. To date, these processes have been extensively studied on the neural level, yet their functional significance for cognitive behaviour remains largely unclear. This project will investigate neural dedifferentiation and its relationship to cognitive performance in the healthy aging brain. To this end, the investigators will use a combination of state-of-the-art technologies including simultaneous transcranial magnetic stimulation (TMS) and high-density electroencephalography (hd-EEG) as well as diffusion tensor imaging (DTI). Perspectives include a better understanding of the relationship between neurophysiological mechanisms and cognitive performance in the healthy aging brain.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Basic Science
Masking
Single (Participant)

Eligibility Criteria

Ages
20 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Informed consent as documented by signature
  • Age between 20-30 or 65-75 years
  • Neurologically healthy, i.e., with no documented or present neurological disease or brain injury
  • Normal or corrected-to-normal visual acuity

Exclusion Criteria

  • Any instable medical condition, in particular epilepsy (past or present, including seizures or febrile convulsions)
  • Any surgical intervention to the brain
  • Heart diseases
  • Implanted medical devices (e.g., cochlear implants, infusion pumps, neurostimulators, pacemakers)
  • History of migraine or strong headaches
  • Sleep deprivation
  • Presence of non-MRI safe metal in the body
  • Drug or alcohol abuse
  • Intake of any medication that is likely to lower seizure threshold
  • Claustrophobia
  • For female participants: in order to participate in the study, female participants in reproductive age need to take a pregnancy test (a standard urine pregnancy test will be provided).
  • For female participants: breastfeeding
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc. of the participant
  • Lack of knowledge of the German language
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Outcomes

Primary Outcomes

Age-related differences in the spatio-temporal patterns of signal propagation

Time Frame: 2 hours

The spatiotemporal patterns of signal propagation, as measured with a combined TMS-hd-EEG approach, in younger and older healthy participants, reflecting age-related differences on the neural level.

Secondary Outcomes

  • Association between the performance in a cognitive test battery and patterns of signal propagation in better- and worse-performers(4 hours)
  • Association between the patterns of signal propagation and the structural properties of the white matter(4 hours)
  • Association between the performance in a cognitive test battery and patterns of signal propagation in younger and older participants(4 hours)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
Extensión multinacional, multicéntrica y de fase abierta con tratamiento activo del estudio MS-LAQ-301 (Allegro) para evaluar la seguridad a largo plazo, la tolerabilidad y el efecto sobre el curso de la enfermedad de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple recurrente. -
EUCTR2009-012989-30-ESTeva Pharmaceutical Industries Ltd1,000
Active, not recruiting
Phase 1
Extensión multinacional, multicéntrica y de fase abierta con tratamiento activo del estudio MS-LAQ-302 (Bravo) para evaluar la seguridad a largo plazo, la tolerabilidad y el efecto sobre el curso de la enfermedad de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple recurrente -
EUCTR2009-015815-42-ESTeva Pharmaceutical Industries Ltd1,245
Active, not recruiting
Phase 3
A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic EsophagitisEosinophilic esophagitis
JPRN-jRCT2051200140Inoue Tomoyoshi33
Completed
Phase 3
A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab* (MSB0010718C) plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer whose Disease did not Progress after Completion of First-Line Platinum-Containing Chemotherapy
NL-OMON55699Pfizer20
Active, not recruiting
Phase 3
clinical trial in patient with locally advance or metastatic cancer of the urinary tract
CTRI/2017/01/007696Pfizer Inc6
Signal Propagation and Its Relationship to... | Clinical Trial